Loading...
•
Sep 30, 2020
ADMA Biologics Q3 2020 Earnings Report
Reported financial results for the third quarter and nine months ended September 30, 2020, and provided an overview of recent progress and accomplishments.
Key Takeaways
ADMA Biologics reported a 42% increase in revenue for the third quarter of 2020, reaching $10.3 million, driven by the commercial ramp-up of BIVIGAM and ASCENIV and a manufacturing supply agreement. However, the company experienced a net loss of $16.9 million, primarily due to increased costs of product revenue, selling, general, and administrative expenses, and research and development expenses.
Total revenues for Q3 2020 were $10.3 million, a 42% increase compared to Q3 2019.
The revenue growth was impacted by the continued commercial ramp up of BIVIGAM and ASCENIV, and by the manufacturing and supply agreement to produce and sell intermediate fractions.
Consolidated net loss for Q3 2020 was $16.9 million, or $(0.19) per basic and diluted share.
ADMA had cash and cash equivalents of $59.7 million as of September 30, 2020.
Forward Guidance
The company anticipates a strong fourth quarter and expects considerable growth in the second half of 2020 versus the first half.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...